The pharmaceutical company Galderma announced that its novel hyaluronic acid dermal filler, Restylane Eyelight, has been approved by the U.S. Food and Drug Administration (FDA) to treat patients with undereye hollows. Experts explained that undereye hollows often give the face an aged appearance, and previous treatments such as topical creams, concealers, and masks have been inadequate. In a recent phase III trial, Galderma’s new dermal filler demonstrated positive safety and efficacy. After 3 months of follow-up, 87% of patients who received the dermal fillers reported diminished undereye hollows and 92% were pleased with their treatment results; after 12 months of follow-up, 84% of patients were still satisfied by their results, and 93% expressed interest in receiving the agent again. Researchers also noted that the results lasted up to 18 months in some patients. Further, the side effects of receiving the dermal fillers were mild and included redness, swelling, tenderness, pain, bruising, itching, or lumps at the injection site. Experts encourage those with undereye hollows to consult their dermatologists before undergoing the treatment.
June 19, 2023